---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-001981"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T22:30:29.855481+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enanta reports Q1 net loss $29M; SPRINT Phase 2 COVID-19 study fully enrolled with data expected May 2023

## Summary
- Revenue $23.6M, down from $27.6M YoY, primarily from MAVYRET royalties.
- Net loss $29.0M ($1.39 loss per share) vs $30.1M ($1.48 loss per share) YoY.
- Cash $241.4M; expects runway into Q4 fiscal 2024.
- Enrollment complete in Phase 2 SPRINT study of EDP-235 (COVID-19); topline data expected May 2023.
- Expects Phase 1 data for EDP-323 (RSV) in Q2 2023; new PLpro and dual hMPV/RSV programs.

## SEC filing metadata
- accession: 0000950170-23-001981
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017023001981/0000950170-23-001981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017023001981/enta-20230207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-001981
- JSON: https://secwatch.observer/filing/0000950170-23-001981.json
- Plain text: https://secwatch.observer/filing/0000950170-23-001981.txt

## Key facts
- Earnings Releases
  ENANTA PHARMACEUTICALS INC reported fiscal first quarter ended December 31, 2022 results: revenue $23.6 million, net income $29.0 million, EPS a loss of $1.39 per diluted common share.
  - Period: fiscal first quarter ended December 31, 2022
  - Revenue: $23.6 million
  - Net income: $29.0 million
  - EPS: a loss of $1.39 per diluted common share
  - Result: reported results
  source text: Total revenue for the three months ended December 31, 2022 was $23.6 million and consisted primarily of $22.6 million of royalty revenue from worldwide net sales of MAVYRET®/MAVIRET®, AbbVie’s eight-week treatment for chronic hepatitis C virus (HCV). For the three months ended December 31, 2021, total royalty revenue was $27.6 million on AbbVie’s sales of MAVYRET/MAVIRET. The decline is primarily a result of continued lower treated patient volumes due to the COVID-19 pandemic. Research and development expenses totaled $40.9 million for the three months ended December 31, 2022, compared to $48.5 million for the three months ended December 31, 2021. The decrease was primarily due to the timing of drug supply manufacturing and preclinical studies in the company’s virology program year over year. General and administrative expenses totaled $12.7 million for the three months ended December 31, 2022, compared to $9.5 million for the three months ended December 31, 2021. This increase was pri
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000095017023001981/0000950170-23-001981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.